Chargement en cours...
Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
BACKGROUND: The IMpassion130 trial demonstrated that adding atezolizumab to nanoparticle albumin-bound (nab)-paclitaxel improved the survival of patients with untreated, advanced, programmed death ligand 1 (PDL1)-positive triple-negative breast cancer (TNBC). In view of the high cost of immunotherap...
Enregistré dans:
| Publié dans: | BMC Health Serv Res |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7315527/ https://ncbi.nlm.nih.gov/pubmed/32580722 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12913-020-05445-6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|